Published in Cancer Weekly, September 7th, 2004
Through the use of its proprietary Morphodoma technology, Morphotek has successfully optimized this antibody.
The antibody was obtained from an ongoing collaboration with The Ludwig Institute For...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.